The investigators propose, as part of the study, to carry out for each patient:

• An analysis of monocytic populations by flow cytometry (CD14, CD16, CD45, CD68, CD115, CCR2, CX3CR1, CD163 and CD206).
• A population assessment of Myeloid-Derived Suppressor Cells (MDSC).
• Assays of cytokines and chemokines involved in inflammation by multiplex analyzes: Il-1 (α and β), Il-4, Il-6, Il-10, Il-13, TNF- α, TGF- β, CRP , leptin, IFN- β.
• Specialized dosages of proteins involved in bone metabolism. RANKL, osteoprotegerin, M-CSF, TRAPCP5.

Inclusion Criteria:

• Major patients followed at the hemophilia treatment reference center,
• Presenting the diagnosis of severe, moderate or minor Hemophilia A / B,
• Having a social security system,
• Obtaining the oral non-objection collection from the patient after information.

Exclusion Criteria:

• Minor patients, under guardianship or curatorship.

• Causes of secondary osteoporosis:

  • Systemic corticosteroid therapy in progress (≥ 3 consecutive months, at a dosage ≥ 7.5 mg / d of prednisone equivalent).
  • other treatment or condition responsible for osteoporosis: prolonged or medicated hypogonadism, untreated active hyperthyroidism, hypercorticism, primary hyperparathyroidism.

• Treatment with biphosphonates, biotherapies or hormone therapy in the treatment of prostate cancer.

It will include adult male patients with hemophilia A or B, severe, moderate or minor.

In addition, the investigators will include patients with Hemophilia A with an inhibitor.